Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19703774 | 0.95 | NPC1 (0.69) | NPC1ALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL19703702 | 0.94 | NPC1 (0.67) | NPC1ALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL19703773 | 0.90 | NPC1 (0.65) | NPC1ALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL2606049 | 0.85 | NPC1 (0.73) | NPC1ALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL19698169 | 0.83 | NPC1 (0.47) | NPC1ALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL15224180 | 0.81 | NPC1 (0.79) | NPC1ALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL19884749 | 0.79 | NPC1 (0.76) | NPC1ALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL19703776 | 0.79 | ALDH1A1 (0.58) | NPC1ALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL14417832 | 0.79 | NPC1 (0.81) | NPC1ALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL9062091 | 0.79 | NPC1 (0.81) | NPC1ALDH1A1HPGDLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | NPC1 2704/4885ALDH1A1 3212/4885HPGD 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.